Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
News & Analysis: Aimmune Therapeutics
AIMT earnings call for the period ending March 31, 2020.
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment.
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
A risk management process slowed the launch of Aimmune’s first product.
A month after the drug's approval, Aimmune is still working on getting it to patients.
AIMT earnings call for the period ending December 31, 2019.
The food allergy specialist just landed its first approval.
The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies.